Liver transplantation for hepatocellular carcinoma: Improving eligibility without compromising outcomes.
| Autor: | Hafeez Bhatti AB; Department of Hepato-Pancreatico-Biliary Surgery and Liver Transplantation, Shifa International Hospital, Islamabad, Pakistan., Qureshi AI; Department of Hepato-Pancreatico-Biliary Surgery and Liver Transplantation, Shifa International Hospital, Islamabad, Pakistan., Tahir R; Department of Hepato-Pancreatico-Biliary Surgery and Liver Transplantation, Shifa International Hospital, Islamabad, Pakistan., Almas T; RCSI University of Medicine and Health Sciences, Dublin, Ireland., Rana A; Department of Interventional Radiology, Shifa International Hospital, Islamabad, Pakistan. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Annals of medicine and surgery (2012) [Ann Med Surg (Lond)] 2021 Jul 10; Vol. 68, pp. 102552. Date of Electronic Publication: 2021 Jul 10 (Print Publication: 2021). |
| DOI: | 10.1016/j.amsu.2021.102552 |
| Abstrakt: | Background: In the context of liver transplantation for hepatocellular carcinoma (HCC), traditional transplant criteria appear restrictive. The objective of the current study was to determine risk factors for recurrence and improve transplant eligibility in patients with HCC. Materials and Methods: This was a retrospective study of patients who underwent living donor liver transplant (LDLT) for HCC (n = 219). Largest tumor diameter, tumor number, AFP and neutrophil to lymphocyte ratio were assessed. Multivariate analysis was performed to develop risk scores. The new model was compared with seven previously published transplant criteria using receiver operator curves. Results: Largest tumor size >3.7 cm [ HR:2.6, P = 0.02 ], and AFP > 600 ng/ml [ HR:4.7, P = 0.001 ] were independent predictors of recurrence. Patients with risk scores of 0, 1-3, 4-6 and 7-9 had recurrence rate of 5.9%, 12.5%, 25% and 58.4% respectively. When compared with Milan criteria, Metro ticket 2.0, AFP model and Samsung criteria; transplant eligibility increased by 31.5%, 22.9%, 8.7%, and 7% respectively. Recurrence rate with the current model was 16/199 (8%) (P < 0.0001) and was comparable with other transplant criteria (6.9-9.1%). On ROC analysis, only Milan criteria (AUC = 0.7, P = 0.001) and the current model (AUC = 0.66, P = 0.01) showed significance for recurrence. All patients with high risk scores within Milan criteria had recurred at 3 years (P = 0.03). Conclusions: Low AFP can be used to select patients for LDLT outside traditional criteria for HCC, with comparable recurrence rates. Competing Interests: None. (© 2021 The Authors.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|